P
Paul M. Steed
Researcher at Durham University
Publications - 10
Citations - 949
Paul M. Steed is an academic researcher from Durham University. The author has contributed to research in topics: Prodrug & Heat shock protein. The author has an hindex of 8, co-authored 10 publications receiving 876 citations.
Papers
More filters
Journal ArticleDOI
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
Yutaka Okawa,Yutaka Okawa,Teru Hideshima,Paul M. Steed,Sonia Vallet,Steven E. Hall,Ken Huang,John R. Rice,Amy F. Barabasz,Brianna Foley,Hiroshi Ikeda,Noopur Raje,Tanyel Kiziltepe,Hiroshi Yasui,Sotaro Enatsu,Kenneth C. Anderson +15 more
TL;DR: The results indicate that blockade of Hsp90 by SNX-2112 not only inhibits MM cell growth but also acts in the bone marrow microenvironment to block angiogenesis and osteoclastogenesis.
Journal ArticleDOI
SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers
Sarat Chandarlapaty,Ayana Sawai,Qing Ye,Anisa Scott,Melanie Silinski,Ken Huang,Patrick Fadden,Jeff Partdrige,Steven C. Hall,Paul M. Steed,Larry Norton,Neal Rosen,David B. Solit +12 more
TL;DR: Hsp90 inhibition with SNX-2112 (delivered as a prodrug) may represent a promising therapeutic strategy for tumors whose growth and survival is dependent on Hsp90 clients.
Journal ArticleDOI
Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents.
Kenneth He Huang,James Marvin Veal,Patrick Fadden,John W. Rice,Jeron Eaves,Jon-Paul Strachan,Amy F. Barabasz,Briana Foley,Barta Thomas E,Wei Ma,Melanie Silinski,Mei Hu,Jeffrey M. Partridge,Anisa Scott,Laura G. Dubois,Tiffany Freed,Paul M. Steed,Andy J. Ommen,Emilie D. Smith,Philip F. Hughes,Angela R. Woodward,Hanson Gunnar J,W. Stephen Mccall,Christopher John Markworth,Lindsay Hinkley,Matthew Jenks,Geng Lifeng,Meredith Lewis,James C. Otto,Bert Pronk,Katleen Verleysen,Steven E. Hall +31 more
TL;DR: A novel class of heat shock protein 90 (Hsp90) inhibitors was developed from an unbiased screen to identify protein targets for a diverse compound library, and optimized analogues exhibited nanomolar antiproliferative activity across multiple cancer cell lines.
Journal ArticleDOI
Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity.
Preeti Putcha,Karin M Danzer,Lisa R. Kranich,Anisa Scott,Melanie Silinski,Sarah R. Mabbett,Carol D. Hicks,James Marvin Veal,Paul M. Steed,Bradley T. Hyman,Pamela J. McLean +10 more
TL;DR: It is found that several compounds prevented αsyn oligomerization as measured by decreased luciferase activity, led to a reduction in high-molecular-mass oligomeric αsyn, and protected against αsyn cytotoxicity.
Journal ArticleDOI
Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis.
John W. Rice,James Marvin Veal,Patrick Fadden,Amy F. Barabasz,Jeffrey M. Partridge,Barta Thomas E,Laura G. Dubois,Kenneth He Huang,Sarah R. Mabbett,Melanie Silinski,Paul M. Steed,Steven E. Hall +11 more
TL;DR: The present results demonstrate that a small molecule Hsp90 inhibitor can impact inflammatory disease processes and provides preclinical validation for consideration of Hsp 90 inhibitors in the treatment of RA.